Side-by-side comparison

NVO vs GILD — Side-by-side comparison

GILD screens cheaper on EV/FCF, GILD has the higher ROIC, GILD has grown revenue faster over five years, and GILD has the cleaner balance sheet by net debt / EBITDA.

NVO

Novo Nordisk A S

Price

$44.96

Market cap

$305.8B

Day %

N/A

GILD

Gilead Sciences

Price

$134.36

Market cap

$128.0B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


NVO Target	Novo Nordisk A S	$305.8B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GILD	Gilead Sciences	$128.0B	19.8x	15.4x	17.9%	3.6%	32.1%	N/A	1.7x	N/A

NVO implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

N/A

FCF yield

N/A

5Y rev CAGR

N/A

GILD implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

15.4x

FCF yield

7.4%

5Y rev CAGR

3.6%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for NVO.

Grade F

/ 100

Quality Scorecard

Build-time composite score for GILD.

Grade B

/ 100